Life sciences deals often involve complex earn-out structures, billion-dollar valuations, and cross-border considerations, making them fertile ground for disputes. This panel brings together dealmakers, counsel, and arbitrators to explore how arbitration is shaping the resolution of M&A disputes in this sector. From drafting pitfalls to jurisdictional and procedural choices, to recurring substantive issues, we’ll examine what’s driving disputes and how parties can mitigate risk in high-stakes transactions.

Intellectual property and medical devices sit at the heart of life sciences disputes, where cutting-edge technology meets complex contractual frameworks. This panel will explore how arbitration is being used to resolve IP and device-related issues in high-value transactions. From licensing and patent rights to regulatory hurdles and cross-border enforcement, discover the trends shaping arbitration in this critical sector.

Private equity and venture capital are fuelling breakthroughs in life science, but when billions are on the line, disputes can derail the most promising deals. This panel dives into the high-stakes world of PE and VC investments, exploring where issues arise and how they are resolved. From valuation battles to governance clashes and exit strategies, hear insider perspectives on managing risk and keeping deals on track.

Curious about how international arbitration is shaping life sciences disputes? This session puts your questions front and centre. A panel of seasoned arbitrators with substantial experience in life sciences arbitrations will share candid insights on what’s working, what’s changing, and where improvements might be needed. Audience and moderator questions submitted in advance will drive a practical, forward-looking discussion.